To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Faculty
Rakesh Popat
Professor
University College London Hospital London, United Kingdom
Consultant Haematologist and Professor of Haematology
TARGET AUDIENCE
These activities are intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma.
LEARNING OBJECTIVES
- Assess the biological rationale for targeting G protein-coupled receptor class C group 5 member D (GPRC5D) in patients with multiple myeloma (MM).
- Evaluate published clinical research establishing the efficacy of GPRC5D-targeted bispecific antibody monotherapy for patients with relapsed/refractory (R/R) MM, and optimally integrate this strategy into current treatment algorithms.
- Understand the scientific justification for combining GPRC5D-targeted bispecific antibodies with other therapies with established efficacy for MM, and review available research data supporting the clinical utilization of these approaches.
- Appraise available data with GPRC5D-targeted chimeric antigen receptor T-cell therapy for patients with R/R MM, and consider the potential role of this strategy.
- Develop an understanding of adverse events associated with GPRC5D-targeted therapies in the treatment of MM, and employ recommended approaches to prevent, ameliorate and manage toxicities.
- Recall the designs of ongoing trials evaluating novel GPRC5D-directed strategies, and as applicable, refer eligible patients for participation.
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Interview: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Lecture: Research To Practice designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation components and post-tests, enables the participant to earn up to 1.25 (interview) or 0.5 (lecture) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THESE CME ACTIVITIES
To receive credit for these activities, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation (interview, lecture).
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of these activities. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Prof Popat — Advisory Committees: GSK, Pfizer Inc, Regeneron Pharmaceuticals Inc; Consulting Agreements: GSK, Johnson & Johnson, Lilly, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: AbbVie Inc, GSK, Pfizer Inc; Speakers Bureaus: AbbVie Inc, GSK, Johnson & Johnson, Pfizer Inc.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
These activities are supported by educational grants from Bristol Myers Squibb and Johnson & Johnson.
Release date: November 20, 2026
Expiration date: November 20, 2027
Bal S et al. Arlocabtagene autoleucel: A GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma. Blood 2026;148(10):1240-50. Abstract
Bal S et al. BMS-986393, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cell therapy, in patients (pts) with relapsed/refractory (RR) multiple myeloma (MM) and 1-3 prior regimens: Updated phase 1 safety and efficacy results. ASH 2024;Abstract 2069.
Chari A et al. Timing and resolution of talquetamab-related dysgeusia in relapsed/refractory multiple myeloma: Longitudinal Waterless Empirical Taste Test and patient-reported outcomes profiles from TALisman. IMS 2026.
Chari A et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study. Lancet Haematol 2025;12(4):e269-81. Abstract
Cohen YC et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 2025;392(2):138-49. Abstract
Kumar S et al. Dual targeting of extramedullary myeloma with talquetamab and teclistamab. N Engl J Med 2026;394(1):51-61. Abstract
Matous JV et al. Updated safety and efficacy of ramantamig (Ram; JNJ-5322) at the recommended phase 2 dose (RP2D), demonstrating feasibility of outpatient dosing (OPD) in relapsed/refractory multiple myeloma (RRMM). IMS 2026;Abstract OA-70.
Mina R et al. Talquetamab-daratumumab in relapsed or refractory myeloma. N Engl J Med 2026;395(7):671-83. Abstract
Rasche L et al. Efficacy and safety from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Analyses at an extended median follow-up. ASCO 2025;Abstract 7528.
Rodriguez-Otero P et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol 2024;25(5):e205-16. Abstract